Literature DB >> 22720219

To respond or not to respond to CD40 agonism: That is the prediction.

Xiaoyan Shi1, David Dornan.   

Abstract

In the context of the clinical development of a CD40-stimulatory monoclonal antibody for the treatment of B-cell cancers, a tumor mRNA-based gene signature reflecting CD40 signaling pathway activation status was identified that could be used to predict responding and non-responding patients with diffuse large B cell lymphoma (DLBCL).

Entities:  

Year:  2012        PMID： 22720219      PMCID： PMC3376969          DOI： 10.4161/onci.1.1.17827

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen.

Authors:  E V Planken; N H Dijkstra; M Bakkus; R Willemze; J C Kluin-Nelemans
Journal:  Br J Haematol       Date:  1996-11       Impact factor: 6.998

2.  Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Authors:  Ranjana Advani; Andres Forero-Torres; Richard R Furman; Joseph D Rosenblatt; Anas Younes; Hong Ren; Kate Harrop; Nancy Whiting; Jonathan G Drachman
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

3.  CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.

Authors:  Bart Burington; Peng Yue; Xiaoyan Shi; Ranjana Advani; Jeffrey T Lau; Jenille Tan; Susanna Stinson; Jeremy Stinson; Thomas Januario; Sven de Vos; Stephen Ansell; Andres Forero-Torres; Grazyna Fedorowicz; Teddy T C Yang; Kristi Elkins; Changchun Du; Sankar Mohan; Nancy Yu; Zora Modrusan; Somasekar Seshagiri; Shang-Fan Yu; Ajay Pandita; Hartmut Koeppen; Dorothy French; Andrew G Polson; Rienk Offringa; Nancy Whiting; Allen Ebens; David Dornan
Journal:  Sci Transl Med       Date:  2011-03-16       Impact factor: 17.956

4.  Linear ubiquitination prevents inflammation and regulates immune signalling.

Authors:  Björn Gerlach; Stefanie M Cordier; Anna C Schmukle; Christoph H Emmerich; Eva Rieser; Tobias L Haas; Andrew I Webb; James A Rickard; Holly Anderton; Wendy W-L Wong; Ueli Nachbur; Lahiru Gangoda; Uwe Warnken; Anthony W Purcell; John Silke; Henning Walczak
Journal:  Nature       Date:  2011-03-31       Impact factor: 49.962

5.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

6.  Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells.

Authors:  T S Lewis; R S McCormick; I J Stone; K Emmerton; B Mbow; J Miyamoto; J G Drachman; I S Grewal; C-L Law
Journal:  Leukemia       Date:  2011-03-11       Impact factor: 11.528

7.  Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax.

Authors:  Jamie L Szocinski; Annette R Khaled; Julie Hixon; Douglas Halverson; Satoshi Funakoshi; William C Fanslow; Ann Boyd; Dennis D Taub; Scott K Durum; Clay B Siegall; Dan L Longo; William J Murphy
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

8.  Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex.

Authors:  Atsushi Matsuzawa; Ping-Hui Tseng; Sivakumar Vallabhapurapu; Jun-Li Luo; Weizhou Zhang; Haopeng Wang; Dario A A Vignali; Ewen Gallagher; Michael Karin
Journal:  Science       Date:  2008-07-17       Impact factor: 47.728

9.  Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis.

Authors:  Cornelia Hömig-Hölzel; Caroline Hojer; Julia Rastelli; Stefano Casola; Lothar J Strobl; Werner Müller; Leticia Quintanilla-Martinez; Andreas Gewies; Jürgen Ruland; Klaus Rajewsky; Ursula Zimber-Strobl
Journal:  J Exp Med       Date:  2008-05-19       Impact factor: 14.307
  9 in total
  1 in total

1.  Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Authors:  Guoqi Song; Huiyun Ni; Linqing Zou; Shukui Wang; Fuliang Tian; Hong Liu; William C Cho
Journal:  Onco Targets Ther       Date:  2016-06-23       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.